Derma Sciences Reports Fourth Quarter, Year-End Result...( PRINCETON N.J. April 1 /- Chair...),Health

PRINCETON, N.J., April 1 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, reported that sales for 2008 rose 47.1% year-over-year, reflecting incremental sales from its First Aid Division (FAD) and higher sales of proprietary advanced wound care products led by MEDIHONEY(R). Sales for the year were $50.2 million vs $34.1 million in 2007. The Company's loss increased consistent with expectations to $4.0 million or $0.10 per share, compared to 2007's loss of $2.3 million or $0.09 per share, as Derma Sciences implemented its advanced wound care growth strategy, integrated FAD into the company and continued its investment in R&D. Fourth quarter 2008 sales were $12.6 million versus $10.7 million in 2007. Net losses diminished each quarter during the year, and the 2008 fourth quarter loss was $0.6 million versus $2.0 million in 2007.

Chairman and CEO Ed Quilty commented, "Our advanced wound care products made great strides in 2008. Sales for our silver alginate product, ALGICELL(R) Ag, nearly doubled to over $1.1 million. Sales of our MEDIHONEY product, launched in October 2007, grew consistently each quarter, and ended the year at $1.5 million in 2008 versus $0.1 million for the final three months of 2007. MEDIHONEY continues to get great media coverage, typified by a cluster of television and print articles reporting that the product was credited for saving a patient's leg from having to be amputated at Long Island Jewish Hospital in January 2009. Its coverage in medical journals continues to be strong, as seven separate articles on the emerging use of MEDIHONEY were published in the major wound care journals since December of 2008.

"In the fourth quarter and early 2009, we launched three additional promising new products," Quilty stated. "Our prop
'/>"/>